Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
PPF leaves Zentiva to Sanofi
PPF Group has bowed out of the competition for the Czech generics maker Zentiva, saying it has "certain doubts about the real value of the company"--and that it doesn't want to end up in a bidding war with Sanofi-Aventis. The news prompted Sanofi to reiterate its 1,050 koruna-per-share offer, which values the company at $2.69 billion.
No word yet from Zentiva management, who quickly rejected PPF's lower offer--950 koruna--and, after some deliberation, came out against Sanofi's, too. As you know, Sanofi already owns 25 percent of Zentiva, while PPF together with an Italian insurer holds 19 percent.
- check out PPF's release
- read the story at MarketWatch
Related Articles:
Zentiva spurns Sanofi's buyout offer
Sanofi launches $1.92B Zentiva offer
Sanofi makes $2 billion generics move
Zentiva board rejects PPF bid
Will Zentiva find itself in bidding war?
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


